...
首页> 外文期刊>World Journal of Gastroenterology >McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma
【24h】

McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma

机译:麦吉尔布里斯班症状评分对可切除的胰头腺癌患者的作用

获取原文
           

摘要

AIM: To evaluate the ability of the McGill Brisbane Symptom Score (MBSS) to predict survival in resectable pancreatic head adenocarcinoma (PHA) patients. METHODS: All PHA patients (n = 83) undergoing pancreaticoduodenectomy at the McGill University Health Center, Quebec between 1/2001-1/2010 were evaluated. Data related to patient and cancer characteristics, MBSS variables, and treatment were collected; univariable and multivariable survival analyses were performed. We obtained complete follow-up until February 2011 in all patients through the database of the provincial health insurance plan of Quebec. The unique health insurance numbers of these patients were used to retrieve information from this database which captures all billable clinical encounters, and ensures 100% actual survival data. RESULTS: Median survival was 23 mo overall: 45 mo for patients with low MBSS, 17 mo for high MBSS (P = 0.005). At twelve months survival was 83.3% (95%CI: 66.6-92.1) vs 58.1% (95%CI: 42.1-71.2) in those with low vs high MBSS, and24 mo survival was 63.8% (95%CI: 45.9-77.1) and 34.0% (95%CI: 20.2-48.2) respectively. In the multivariate Cox model (stratified by chemotherapy), after addition of clinically meaningful covariates, MBSS was the variable with the strongest association with survival (HR = 2.63; P = 0.001). Adjuvant chemotherapy interacted with MBSS category such that only high MBSS patients accrued a benefit. In univariate analysis we found a lower mortality in high MBSS but not low MBSS patients receiving adjuvant chemotherapy. This interaction variable, on Cox model, resulted in an adjusted mortality HR for the high MBSS (compared to low MBSS) of 4.14 (95%CI: 1.48-11.64) without chemotherapy and 2.11 (95%CI: 1.06-4.17) with chemotherapy. CONCLUSION: The MBSS is a simple prognostic tool for resectable PHA. Preoperative categorization of patients according to the MBSS allows effective stratification of patients to guide therapy.
机译:目的:评估麦吉尔布里斯班症状评分(MBSS)预测可切除的胰头腺癌(PHA)患者生存的能力。方法:对在魁北克省麦吉尔大学健康中心于2010年1月21日至1月1日接受胰十二指肠切除术的所有PHA患者(n = 83)进行了评估。收集与患者和癌症特征,MBSS变量和治疗有关的数据;进行了单变量和多变量生存分析。通过魁北克省健康保险计划的数据库,我们对所有患者进行了完整的随访,直至2011年2月。这些患者的独特健康保险号码被用于从该数据库中检索信息,该数据库捕获所有可计费的临床遭遇,并确保100%的实际生存数据。结果:总体中位生存期为23个月:低MBSS患者为45个月,高MBSS患者为17个月(P = 0.005)。在12个月时,MBSS较低和较高的患者生存率为83.3%(95%CI:66.6-92.1),而生存率为58.1%(95%CI:42.1-71.2),24 mo生存率为63.8%(95%CI:45.9-77.1) )和34.0%(95%CI:20.2-48.2)。在多变量Cox模型(通过化学治疗分层)中,添加了具有临床意义的协变量后,MBSS是与生存率关联最强的变量(HR = 2.63; P = 0.001)。辅助化疗与MBSS类别相互作用,因此只有高MBSS患者才受益。在单因素分析中,我们发现接受辅助化疗的高MBSS患者死亡率较低,但低MBSS患者的死亡率却不低。在Cox模型上,此相互作用变量导致未经化疗的高MBSS(相对于低MBSS)的调整后死亡率HR为4.14(95%CI:1.48-11.64),经化学疗法为2.11(95%CI:1.06-4.17) 。结论:MBSS是可切除PHA的简单预后工具。根据MBSS对患者进行术前分类,可以对患者进行有效分层以指导治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号